Literature DB >> 29437490

H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program.

Peter J Leary1, Edward Hess2, Anna E Barón2,3, Kelley R Branch1, Gaurav Choudhary4,5, Catherine L Hough1, Bradley A Maron6,7,8, David D Ralph1, John J Ryan9, Ryan J Tedford10, Noel S Weiss1, Roham T Zamanian11, Tim Lahm12,13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29437490      PMCID： PMC6006405          DOI： 10.1164/rccm.201801-0048LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.

Authors:  Jiyoong Kim; Akiko Ogai; Satoshi Nakatani; Kazuhiko Hashimura; Hideaki Kanzaki; Kazuo Komamura; Masanori Asakura; Hiroshi Asanuma; Soichiro Kitamura; Hitonobu Tomoike; Masafumi Kitakaze
Journal:  J Am Coll Cardiol       Date:  2006-09-14       Impact factor: 24.094

2.  H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study.

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Richard A Kronmal; Joao A Lima; David D Ralph; Corey E Ventetuolo; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2014-11

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

4.  Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release.

Authors:  M R Bristow; N E Kantrowitz; W D Harrison; W A Minobe; W S Sageman; M E Billingham
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

5.  Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.

Authors:  Peter J Leary; Ryan J Tedford; David A Bluemke; Michael R Bristow; Susan R Heckbert; Steven M Kawut; Eric V Krieger; Joao A Lima; Carolina S Masri; David D Ralph; Steven Shea; Noel S Weiss; Richard A Kronmal
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

6.  Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary
Journal:  Circulation       Date:  2016-02-12       Impact factor: 29.690

7.  A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.

Authors:  Hiroyuki Takahama; Hiroshi Asanuma; Shoji Sanada; Masashi Fujita; Hideyuki Sasaki; Masakatsu Wakeno; Jiyoong Kim; Masanori Asakura; Seiji Takashima; Tetsuo Minamino; Kazuo Komamura; Masaru Sugimachi; Masafumi Kitakaze
Journal:  Basic Res Cardiol       Date:  2010-09-18       Impact factor: 17.165

8.  Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis.

Authors:  Zhi Zeng; Liang Shen; Xixian Li; Tao Luo; Xuan Wei; Jingwen Zhang; Shiping Cao; Xiaobo Huang; Yasushi Fukushima; Jianping Bin; Masafumi Kitakaze; Dingli Xu; Yulin Liao
Journal:  Clin Sci (Lond)       Date:  2014-10       Impact factor: 6.124

9.  Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function.

Authors:  Tao Luo; Baihe Chen; Zonglei Zhao; Nvqin He; Zhi Zeng; Bing Wu; Yasushi Fukushima; Meng Dai; Qiaobing Huang; Dingli Xu; Jianping Bin; Masafumi Kitakaze; Yulin Liao
Journal:  Basic Res Cardiol       Date:  2013-03-07       Impact factor: 17.165

10.  Accuracy and completeness of mortality data in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Noreen Arnold; Charles Maynard; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-04-10
  10 in total
  5 in total

Review 1.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database.

Authors:  Tim Lahm; Edward Hess; Anna E Barón; Thomas M Maddox; Mary E Plomondon; Gaurav Choudhary; Bradley A Maron; Roham T Zamanian; Peter J Leary
Journal:  Chest       Date:  2020-10-05       Impact factor: 9.410

Review 3.  The right treatment for the right ventricle.

Authors:  Joanne A Groeneveldt; Frances S de Man; Berend E Westerhof
Journal:  Curr Opin Pulm Med       Date:  2019-09       Impact factor: 3.155

4.  Histamine H2 Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women's Health Initiative.

Authors:  Sophia R Larson; Alexi L Vasbinder; Kerryn W Reding; Peter J Leary; Kelley R Branch; Aladdin H Shadyab; Karen C Johnson; Bernhard Haring; Robert Wallace; JoAnn E Manson; Garnet Anderson; Richard K Cheng
Journal:  J Am Heart Assoc       Date:  2022-02-22       Impact factor: 6.106

5.  Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.

Authors:  Bradley A Maron; Evan L Brittain; Edward Hess; Stephen W Waldo; Anna E Barón; Shi Huang; Ronald H Goldstein; Tufik Assad; Bradley M Wertheim; George A Alba; Jane A Leopold; Horst Olschewski; Nazzareno Galiè; Gerald Simonneau; Gabor Kovacs; Ryan J Tedford; Marc Humbert; Gaurav Choudhary
Journal:  Lancet Respir Med       Date:  2020-07-27       Impact factor: 30.700
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.